"West Kazakhstan Marat Ospanov Medical Unversity" Repository

Some Serologic Biomarkers of Multiple Sclerosis Activity: A Narrative Review

Show simple item record

dc.contributor.author Khamidulla, Alima A.
dc.contributor.author Urasheva, Zhanylsyn U.
dc.contributor.author Kabdrakhmanova, Gulnar B.
dc.contributor.author Yermagambetova, Aigul P.
dc.contributor.author Utegenova, Aigerim B.
dc.date.accessioned 2024-07-19T06:25:00Z
dc.date.available 2024-07-19T06:25:00Z
dc.date.issued 2024
dc.identifier.uri http://localhost:8080/xmlui/handle/123456789/381
dc.description Interferon-beta (IFN-𝛽) preparations represent a well-established cohort of pharmaceu tical agents employed for immunomodulation in individuals diagnosed with multiple sclerosis (MS). The clinical courses and manifestations of MS exhibit considerable variability, ranging from mild forms to progressive stages characterized by the development of irreversible clinical deficits with limited responsiveness to standard therapeutic interventions. Notably, highly effective treatments have been developed and have become readily accessible in recent years. The imperative for reliable markers for disease detection, staging, and prognosis prediction arises. This review presents some serologic biomarkers of MS activity, such as antibodies to IFN-𝛽, MxA, viperin, NfL, and IL-17 , which are of interest for predicting MS activity and may contribute to informed decisions regarding optimal therapeutic strategies. ru
dc.description.abstract Interferon-beta (IFN-𝛽) preparations represent a well-established cohort of pharmaceu tical agents employed for immunomodulation in individuals diagnosed with multiple sclerosis (MS). The clinical courses and manifestations of MS exhibit considerable variability, ranging from mild forms to progressive stages characterized by the development of irreversible clinical deficits with limited responsiveness to standard therapeutic interventions. Notably, highly effective treatments have been developed and have become readily accessible in recent years. The imperative for reliable markers for disease detection, staging, and prognosis prediction arises. This review presents some serologic biomarkers of MS activity, such as antibodies to IFN-𝛽, MxA, viperin, NfL, and IL-17 , which are of interest for predicting MS activity and may contribute to informed decisions regarding optimal therapeutic strategies.Interferon-beta (IFN-𝛽) preparations represent a well-established cohort of pharmaceu tical agents employed for immunomodulation in individuals diagnosed with multiple sclerosis (MS). The clinical courses and manifestations of MS exhibit considerable variability, ranging from mild forms to progressive stages characterized by the development of irreversible clinical deficits with limited responsiveness to standard therapeutic interventions. Notably, highly effective treatments have been developed and have become readily accessible in recent years. The imperative for reliable markers for disease detection, staging, and prognosis prediction arises. This review presents some serologic biomarkers of MS activity, such as antibodies to IFN-𝛽, MxA, viperin, NfL, and IL-17 , which are of interest for predicting MS activity and may contribute to informed decisions regarding optimal therapeutic strategies. ru
dc.language.iso en ru
dc.publisher West Kazakhstan Medical Journal ru
dc.subject multiple sclerosis ru
dc.subject serologic biomarkers ru
dc.subject disease activity ru
dc.subject neuroimmunology ru
dc.subject treatment ru
dc.title Some Serologic Biomarkers of Multiple Sclerosis Activity: A Narrative Review ru
dc.type Article ru


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account